Site Editor

Leo I. Gordon, MD, FACP

Advertisement
Advertisement

First-Line Treatment Patterns and Outcomes Offer Considerations for Future Trial Design in Mantle Cell Lymphoma

By: Julia Fiederlein
Posted: Friday, September 16, 2022

Peter Martin, MD, of the New York-Presbyterian Hospital, and colleagues conducted a study to evaluate the first-line treatment patterns and outcomes, as well as the roles of autologous stem cell transplantation (ASCT) and maintenance therapy with rituximab, in patients with mantle cell lymphoma. The results of this retrospective analysis of two large, real-world cohorts, which were published in the Journal of Clinical Oncology, provide additional considerations for the design of future trials evaluating new treatment regimens in this setting.

“Only one in four young patients received cytarabine or ASCT consolidation, suggesting the need to develop treatments that can be delivered effectively in routine clinical practice,” the investigators commented. “Together with the validation cohort, data support future clinical trials exploring regimens without ASCT consolidation in young patients, whereas maintenance therapy with rituximab should be considered for patients after first-line treatment with bendamustine plus rituximab and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).”

Using the Flatiron Health electronic record–derived de-identified database, the investigators evaluated the treatment patterns and outcomes of 4,216 patients with mantle cell lymphoma. The efficacy findings with ASCT and maintenance therapy with rituximab were validated in an independent cohort of 1,168 patients from 12 academic centers.

Bendamustine plus rituximab was the most frequently administered first-line therapy. A total of 30.5% and 23.5% of the patients younger than age 65 received cytarabine-based induction therapy and ASCT, respectively. There was no significant association found between ASCT and real-world time to next treatment (P = .10) or overall survival (P = .4). Bendamustine plus rituximab followed by maintenance therapy with rituximab seemed to be associated with longer durations of real-world time to next treatment (P < .001) and overall survival (P < .001) than bendamustine plus rituximab alone. The efficacy findings appeared to be consistent in the validation cohort.

Disclosure: For full disclosures of the study authors, visit ascopubs.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.